Welcome to our dedicated page for Glycomimetics SEC filings (Ticker: GLYC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Glycomimetics’ SEC disclosures can feel like decoding complex carbohydrate chemistry—especially when each 8-K details a new clinical milestone or a Form 4 signals executive confidence in an upcoming sickle-cell trial. If you’ve searched “Glycomimetics SEC filings explained simply,” you’re not alone.
Stock Titan turns that complexity into clarity. Our AI scans every document the moment it hits EDGAR, then delivers plain-English takeaways—so you can grasp efficacy data, financing terms, or partner updates in minutes, not hours. Whether you need the latest “Glycomimetics quarterly earnings report 10-Q filing” or want real-time alerts for “Glycomimetics Form 4 insider transactions real-time,” all the information is gathered and summarized in one place.
Use the platform to:
- Track “Glycomimetics insider trading Form 4 transactions” and spot buying or selling before material events.
- Read a “Glycomimetics annual report 10-K simplified” that highlights R&D spend, cash runway, and pipeline timelines.
- Dig into a “Glycomimetics proxy statement executive compensation” without wading through legalese.
- Stay informed with “Glycomimetics 8-K material events explained,” from trial setbacks to partnership announcements.
- Access concise “Glycomimetics earnings report filing analysis” that connects financials to ongoing studies.
Why it matters: Understanding Glycomimetics’ work on glycomimetic drugs for cancer and sickle cell hinges on knowing when trial phases advance, how much runway cash remains, and what “Glycomimetics executive stock transactions Form 4” reveal about management sentiment. With AI-powered summaries, real-time updates, and historical archives, “understanding Glycomimetics SEC documents with AI” is finally straightforward.
Form 144 Overview: GRAIL, Inc. (symbol GRAL) has filed a Form 144 indicating that an affiliate plans to sell 9,692 common shares on or about 06/30/2025 through Morgan Stanley Smith Barney LLC.
Key transaction details
- Seller: Joshua J. Ofman (address provided in the filing).
- Securities: Common stock obtained as restricted stock units (RSUs) on 04/30/2025.
- Shares to be sold: 9,692 (aggregate market value $468,995.88).
- Total shares outstanding: 35,973,494, so the proposed sale equals roughly 0.03 % of outstanding shares.
- Exchange: NASDAQ.
Recent insider activity: The filing discloses two prior sales by the same individual during the past three months: 48,213 shares on 05/02/2025 for $1,635,867.09 and 9,692 shares on 06/12/2025 for $410,019.09, some of which were executed under a Rule 10b5-1 trading plan.
Implications for investors: While the absolute dollar amount (~$469k) is modest relative to GRAIL’s total market capitalization implied by the shares outstanding, the notice continues a pattern of insider selling totaling 57,905 shares (~$2.0 million) in the last quarter. Investors often monitor such activity for sentiment cues, although Form 144 filings do not necessarily signal negative fundamentals and may reflect routine diversification or tax-planning.
Effective June 30, 2025, the Statement of Additional Information (SAI) for John Hancock Financial Opportunities Fund (ticker BTO), John Hancock Investors Trust and John Hancock Premium Dividend Fund is updated to reflect two governance changes:
- Paul Lorentz has resigned as a non-independent Trustee of each fund.
- Kristie M. Feinberg, already serving as each fund’s President and CEO of John Hancock Investment Management, has been appointed as a non-independent Trustee effective the same date and will stand for shareholder election in 2026.
The SAI now lists Ms. Feinberg’s extensive leadership background, including her roles at Manulife Investment Management, Invesco and Oppenheimer Funds, underscoring her experience in finance, strategy and product distribution. The board-class assignment for the Financial Opportunities Fund and Premium Dividend Fund places her term expiring in 2026. The John Hancock Fund Complex comprises 186 funds as of April 30, 2025.
No portfolio, financial or strategic policy changes are disclosed; the supplement is solely a board-composition update, to be read in conjunction with the current SAI.
Form 4 filing for GlycoMimetics, Inc. (GLYC) discloses that Fairmount Funds Management LLC, together with affiliated entities (Fairmount Healthcare Fund II L.P., Tomas Kiselak and Peter Harwin), received a grant of 9,023 stock options on 23 Jun 2025. The option has an exercise price of $15.30 and vests in full on the earlier of 23 Jun 2026 or the company’s next annual shareholder meeting, contingent on continued service.
The options are held indirectly by Mr. Harwin for the benefit of investment vehicles managed by Fairmount, which collectively qualify as 10% owners and directors by deputization. Following the grant, the reporting persons own 9,023 derivative securities (no change to non-derivative common share holdings is reported).
No purchase or sale of already-outstanding common shares occurred; the filing represents a routine director compensation award. The size of the grant is immaterial relative to GlycoMimetics’ public float and does not meaningfully affect ownership concentration or potential dilution.
Form 4 filing overview
On June 23, 2025, GlycoMimetics, Inc. (GLYC) disclosed that director Jonathan Violin received a stock option covering 9,023 ordinary shares at an exercise price of $15.30 per share. The award vests in full on the earlier of June 23, 2026 or the company’s next annual shareholder meeting, provided he remains in service, and expires on June 23, 2035. The option is held directly by Violin; no open-market purchases or sales of common stock were reported, and Table I shows no changes in non-derivative share ownership.
The filing represents a routine equity incentive grant to a non-employee director. While it increases Violin’s long-term exposure to the company’s equity, it does not, by itself, indicate a change in insider sentiment or the firm’s financial outlook.
On June 23, 2025, GlycoMimetics, Inc. (GLYC) director David Charles Lubner filed a Form 4 reporting the grant of 9,023 non-qualified stock options at an exercise price of $15.30 per share. The options were acquired for $0.00 and will vest in full on the earlier of June 23, 2026 or the company’s next annual shareholder meeting, subject to continued board service. They carry a 10-year term, expiring June 23, 2035, and are held directly by the director. No open-market purchases, sales, or dispositions of common shares were reported. The filing represents a routine equity-compensation award and does not convey new information about GlycoMimetics’ operating performance, strategy, or near-term cash flows.
Schedule 13D filing (event date 06/13/2025) discloses that Fairmount Funds Management LLC and its affiliated investment vehicle Fairmount Healthcare Fund II L.P., together with principals Peter Evan Harwin and Tomas Kiselak, have accumulated a beneficial stake capped at 3,124,220 Crescent Biopharma, Inc. ordinary shares (CUSIP G2545C104).
The position represents exactly 19.99 % of Crescent’s 13,892,562 outstanding ordinary shares as of 16 June 2025. The stake is composed of:
- 1,387,866 ordinary shares held outright
- 1,736,000 ordinary shares issuable upon conversion of 1,736 Series A non-voting convertible preferred shares
- 354 ordinary shares issuable upon exercise of pre-funded warrants
All voting and dispositive power over the entire block is shared; none of the reporting persons holds sole power. Source of funds is designated “AF” (affiliate funds).
Beneficial-ownership limitations apply: (i) Pre-funded warrants are subject to a 9.99 % ownership cap; (ii) Series A preferred shares cannot be converted if the holder would exceed a 19.99 % stake. Once Fairmount and its affiliates own ≤9 % of the ordinary shares, the preferred-share cap will automatically drop to 9.99 %.
No other material transactions, earnings data, or legal proceedings are disclosed in this filing.
Form 3 overview: On June 23, 2025, officer Ryan Lynch filed an initial statement of beneficial ownership after a multi-step transaction in which GlycoMimetics, Inc. merged with Crescent Biopharma, Inc., adopted the Crescent Biopharma, Inc. name and, on June 16, 2025, redomiciled from Delaware to the Cayman Islands. The filing establishes Lynch’s baseline insider position in the newly constituted issuer (ticker: CBIO).
Equity award details: Lynch, who serves as Treasurer, Senior Vice President of Finance and Chief Accounting Officer, reports a stock option for 105,706 ordinary shares at an exercise price of $6.16. The award originated from his pre-merger Crescent option and now entitles him to acquire an identical number of Cayman ordinary shares. Vesting is 25 % on December 27 2025, with the balance vesting in equal monthly instalments through December 27 2028, contingent upon continued service.
Ownership structure and timing: All derivative securities are held directly; no non-derivative share ownership is reported. The Form 3 provides the first Section 16 disclosure for Lynch following the June 13 2025 closing of the merger, allowing investors to track future changes to his stake.
FAQ
What is the current stock price of Glycomimetics (GLYC)?
What is the market cap of Glycomimetics (GLYC)?
What is the primary focus of Glycomimetics Inc?
How does Glycomimetics develop its drug candidates?
Which therapeutic areas does the company target?
How is the product pipeline structured at Glycomimetics?
What differentiates Glycomimetics from other biotechnology companies?
How does Glycomimetics support its research and development efforts?
What are the main challenges faced by clinical-stage biotechnology companies like Glycomimetics?
How does Glycomimetics ensure the rigor of its clinical research?
